Abstract: The invention relates to an engineered glomerular endothelial cell comprising a reduction in expression of a human leukocyte antigen and its use in an in vitro method for determining the likelihood of occurrence of a non-HLA antibody mediated rejection against a renal allograft in an individual in need thereof. The inventors have observed that by suppressing expression of HLA class I and II molecules it was possible to obtain a cell able to bind non-HLA antibodies. The in vitro diagnostic method has been validated on a cohort of patients.